<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Monoclonal antibodies that define HLA-DR antigen bind to a variety of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, such as Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0002861'>melanoma</z:hpo> cells grown in vitro and with the spent medium of these cultures </plain></SENT>
<SENT sid="1" pm="."><plain>Two radioimmunoassays have been developed to detect HLA-DR antigen circulating in human sera </plain></SENT>
<SENT sid="2" pm="."><plain>The inhibition assay is based on the inhibition of binding of monoclonal antibodies against HLA-DR to the target preparation; the double-determinant assay traces antigen bound by a solid-phase monoclonal antibody by the use of a second 125I-labeled antibody </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-six of 39 sera from patients with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastoid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 2 of 29 sera from patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, and 5 of 31 sera from patients with advanced metastatic <z:hpo ids='HP_0002861'>melanoma</z:hpo> showed increased levels of HLA-DR antigen, whereas none of 28 sera from patients with other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> had increased levels of HLA-DR antigen, and only 2 of 155 sera from healthy donors bound monoclonal antibodies to HLA-DR at detectable levels </plain></SENT>
<SENT sid="4" pm="."><plain>The detection of circulating HLA-DR antigen in sera of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients may be useful in monitoring patients with certain <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>